GLP-1 obesity medications, such as Ozempic and Wegovy, play a significant role in weight management, but their effectiveness varies among individuals. Researchers at the University of Alberta are exploring the impact of energy metabolism and individual factors on the success of…
A recent study published in the journal Childhood Obesity reveals that approximately 16.8% of children aged 10 to 17 who began treatment with GLP-1 receptor agonist medications de…
Recent lawsuits have emerged against the makers of GLP-1 drugs like Ozempic and Wegovy, alleging insufficient warnings about a rare vision loss condition known as NAION. While stu…
The FDA has granted approval for Mounjaro (tirzepatide) to reduce cardiovascular risk in individuals with type 2 diabetes, marking a significant development in diabetes management…
The Medicines and Healthcare products Regulatory Agency (MHRA) has authorized orforglipron, making the UK the first country in Europe to approve this GLP-1 tablet for weight manag…
Research from the University of Hong Kong indicates that GLP-1 medications may help prevent lung scarring in individuals with type 2 diabetes following COVID-19. The study highlig…
In a stunning twist of regulatory fate, the FDA has issued new hair-raising guidelines for users of GLP-1 drugs like Ozempic and Mounjaro, warning of a 37-68% increased risk of ha…